Race to Decode Human Genome as Volatile as Biotech Stocks
By Carolyn Marshall
nextwavestocks.com
“I'm at a loss to understand why people are upset with Celera,” said Stephen Push, Celera's new director of investor relations.
By the way, I checked to see what my 1999 picks would
have done if I'd left them unattended...+220%, so I
paid a 40% penalty for churning this past year. As far
as missing out on this one--I'm sure you saw my message
on the nifty thread, well, it is unlikely I'd have stayed
concentrated in the three picks that I happened to hold
in August--and they'd only have bought me an extra ten or 20%.
So that is not so bad.
Best of luck for 2000!
My New Years resolutions include limiting to one post
a day, an hour on the net for every two hours reading
(some of that is looking at meteorologic numerical
model solutions, so less room for the biotech hobby
for sure) and I'll be recording all my thoughts for
trades in a diary--I think that will help reduce the churn.
The lobster bisque, the smoked salmon, the lamb,
the mousse--I think I'm finally through digesting
most of the New Years Eve meal--maybe now I can go
back to sleep--but did not drink anything besides
sparkling Mount Rainier glacier water--that helps. |
